Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Medtronic
Baxter
Mallinckrodt
Boehringer Ingelheim

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,361,335

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,361,335
Title:Methods for using an elastase
Abstract: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.
Inventor(s): Franano; F. Nicholas (Kansas City, MO)
Assignee: Proteon Therapeutics, Inc. (Kansas City, MO)
Application Number:11/454,405
Patent Claims:1. A method of using an elastase to increase the diameter of an artery or the diameter of a vein in a human subject, the method comprising: locally administering to the wall of the artery or the wall of the vein in the human subject a composition comprising the elastase in a dose sufficient to cause enlargement of the diameter of the artery or the diameter of the vein.

2. The method of claim 1, wherein the composition comprises a pancreatic elastase.

3. The method of claim 1 or 2, wherein the composition is administered by a catheter.

4. The method of claim 1 or 2, wherein the composition is administered directly into the wall of the artery or the wall of the vein.

5. The method of claim 1 or 2, wherein the artery or the vein is obstructed.

6. The method of claim 1 or 2, wherein the composition is administered to an obstructed coronary artery.

7. The method of claim 1 or 2, wherein the artery or the vein is susceptible to obstruction by intimal hyperplasia.

8. The method of claim 1 or 2, wherein the composition does not comprise a collagenase.

9. The method of claim 1 or 2, wherein the composition is administered to the exterior of the artery or the exterior of the vein.

10. The method of claim 1 or 2, wherein the human subject is in need of prophylactic treatment.

11. The method of claim 1 or 2, wherein the method further comprises inserting a portion of a delivery apparatus into the wall of the artery or the wall of the vein.

12. The method of claim 4, wherein the artery or the vein is obstructed by intimal hyperplasia.

13. The method of claim 5, wherein the artery or the vein is obstructed by stenosis.

14. The method of claim 13, wherein the obstruction permits passage of an insufficient volume of blood prior to administering the composition.

15. The method of claim 14, wherein the obstruction is a stenosis.

16. The method of claim 7, wherein the composition is administered to the wall of a vein.

17. The method of claim 7, wherein the vein is connected to an arteriovenous hemodialysis graft.

18. The method of claim 7, wherein the vein is for use in hemodialysis.

19. The method of claim 18, further comprising connecting the vein to an artery via a graft.

Details for Patent 7,361,335

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Advance Biofactures SANTYL collagenase VIAL 101995 001 1965-06-04   Start Trial Proteon Therapeutics, Inc. (Kansas City, MO) 2019-09-24 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,361,335

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Baxter
AstraZeneca
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.